Amadix

Founded in 2010, AMADIX is a leading molecular diagnostics company, focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. Our mission is to extend people’s lives by developing disruptive technologies to detect the tumor many years before the symptoms appear. The company’s products are oriented towards non-invasive early cancer detection, avoiding the complications of existing invasive procedures, such as tumor biopsies. The company’s strategy is the global commercialization of disruptive discoveries in cancer diagnostics, extending people’s lives, improving the survival of cancer patients and helping them to avoid unnecessary invasive procedures, while reducing healthcare costs. To this end, AMADIX collaborates with research groups from around the world to identify and develop next-generation biomarkers for cancer diagnostics.